secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0000950170-24-066545
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus closes $75M sale of royalty and milestone rights to Ligand
-----------------------------------------------------------------

- Received $75M on May 30, 2024, for sale of milestone and royalty rights to Ligand Pharmaceuticals.
- Sold 31.875% of development/regulatory/commercial milestone payments under five license agreements with BMS, Incyte, Merck, UroGen, Gilead.
- Sold 18.75% of royalties from those agreements and 2.625% synthetic royalty on botensilimab/balstilimab net sales.
- Transaction closed May 29, 2024; proceeds net of certain expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024066545/0000950170-24-066545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024066545/agen-20240529.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-066545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer